Switching from Nitrate Therapy to Ranolazine in Patients with Coronary Artery Disease Receiving Phosphodiesterase Type-5 Inhibitors for Erectile Dysfunction
| Autor: | Dioma U. Udeoji, Ernst R. Schwarz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
lcsh:R5-920 arteriosclerosis business.industry erectile dysfunction Ranolazine Phosphodiesterase Case Report General Medicine Arteriosclerosis medicine.disease Bioinformatics Angina Coronary artery disease myocardial ischemia Erectile dysfunction Blood pressure Internal medicine Concomitant phosphodiesterase type-5 inhibitors medicine Cardiology business lcsh:Medicine (General) medicine.drug |
| Zdroj: | Clinical Medicine Insights: Case Reports, Vol 2014, Iss 7, Pp 131-134 (2014) Clinical Medicine Insights. Case Reports Clinical Medicine Insights: Case Reports, Vol 7 (2014) |
| ISSN: | 1179-5476 |
| Popis: | Coronary artery disease (CAD) and erectile dysfunction (ED) frequently coexist. The introduction of phosphodiesterase type-5 (PDE-5) inhibitors has revolutionized medical management of organic ED; however, in patients with angina pectoris, a common symptom of CAD, coadministration of PDE-5 inhibitors and nitrates has been implicated in CAD-related deaths following sexual activity. The mechanism of action of PDE-5 inhibitors results in a potential cumulative drop in blood pressure (BP); thus, these agents are contraindicated in patients receiving nitrates. Beta-blockers and calcium channel antagonists are considered the mainstays of antianginal therapy, but may not be tolerated by all patients. Ranolazine is an antianginal agent that produces minimal reductions in heart rate and BP. Here we report three cases of men with CAD, chronic angina, and concomitant ED. We describe our treatment approach in these patients, using ranolazine as a potential substitute to nitrate therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|